Business and Finance

Charley Maxwell explains why Annex 21 is not just a regulatory hurdle, but a key commercial risk point.

Roel van den Akker examines how the industry might evolve its trade, distribution, and payer strategies to scale GLP-1s for mass demand.

In today’s Pharma Pulse, Walgreens reshapes pharmacist roles, pharmacies expand injectable access, GoodRx and Eli Lilly broaden GLP-1 access, radiopharma investment grows, and AbbVie signs a $745 million Haisco licensing deal.

Roel van den Akker evaluates how blockbuster GLP-1s may shift broader commercialization trends.

In a Q&A, Traci Miller discusses the evolving role of hub services as well as their commercial value.

Lilly's Foundayo and Zepbound KwikPen are now available on GoodRx for self-pay access.

In this week’s Pharma Pulse, tariffs reshape drug supply, a fragile ceasefire tests global pharma, Wegovy goes higher-dose, and patients still can't get appointments fast enough.

In today’s Pharma Pulse, Shionogi acquires global rights to the ALS treatment Radicava, and experts monitor drug supply chains as the U.S.-Iran conflict drives up logistics costs.

Amber Hussain-Siddique says operational discipline in inventory and logistics is the vital, yet overlooked, key to sustaining low-cost generic drug supplies in the U.S.

In today’s Pharma Pulse, Eli Lilly calls for the U.K. government to overhaul its drug pricing framework and the FDA approves Ponlimsi.

Nareda Mills explains why patient services teams are more than support, but strategic drivers for brands.

Pharma can optimize DTP strategies by leveraging data on affordability and patient behavior.

New Benefit 360 and Direct Fund models aim to bridge the gap between clinical eligibility and employer-sponsored coverage.

Workflow alignment, e-prescribing integration, and behavior change strategies are critical to reducing friction across the direct-to-patient ecosystem.

Jordan Armstrong outlines how adaptable DTP programs can reduce barriers and accelerate patient access to therapy.

Shifting cost dynamics and infrastructure capabilities are prompting manufacturers to reassess traditional distribution channels.

Brok Vandersteen explains how life sciences companies can strategically adopt DTP models for better patient access and commercial success.

Kristine McGaughey, vice president of Implementation at ConnectiveRx, shares her insights on timing, strategy, and planning to ensure a smooth therapy launch.

Jordan Armstrong, VP of Business Development at AssistRX, explains how companies can tailor direct-to-patient strategies into their commercialization plans.

Kroger will offer the Zepbound KwikPen at its participating retail pharmacies.

Evaluate’s 2026 analysis finds that rare disease therapies are set for continued growth—potentially exceeding $400 billion in sales by 2032.

Eli Lilly is investing $3 billion over the next decade to build a localized manufacturing and supply system in China.

Hims & Hers will offer branded semaglutide instead of compounded GLP-1 drugs.

The FDA granted a rapid 55-day approval for J&J’s combination of teclistamab and daratumumab hyaluronidase-fihj for multiple myeloma treatment.

CVS Health and Google Cloud will launch Health100 this year, an AI-driven healthcare engagement platform.